eXoZymes (NASDAQ:EXOZ) Shares Down 1.6% – Time to Sell?

eXoZymes Inc. (NASDAQ:EXOZ) fell 1.6% on Friday . The stock traded as low as $6.85 and last traded at $6.97. Approximately 7,051 shares were traded during mid-day trading, a decline of 50% from the average session volume of 14,113 shares. The stock had previously closed at $7.08.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of eXoZymes in a research note on Friday, May 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, eXoZymes presently has a consensus rating of “Sell”.

eXoZymes Stock Performance

The stock’s 50-day simple moving average is $8.74 and its 200 day simple moving average is $9.40. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.32 and a current ratio of 1.32. The company has a market capitalization of $64.19 million, a PE ratio of -6.11 and a beta of 2.73.

eXoZymes (NASDAQ:EXOZ) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.28) earnings per share (EPS) for the quarter.

eXoZymes Company Profile

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.